| Outcome Measures: |
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞), Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose | Secondary: Area Under the Concentration Versus Time Curve From Hour 0 to 168 Hours After Dosing (AUC0-168h), Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose|Plasma Concentration at 168 Hours After Dosing (C168h), 168 hours post-dose|Maximum Observed Plasma Concentration (Cmax), Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose|Time to Maximum Observed Plasma Drug Concentration (Tmax), Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose|Apparent Terminal Phase Half-life (t½), Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose|Number of Participants Experiencing Adverse Events (AEs), An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment., Up to 14 days post-dose|Number of Participants Discontinued From Study Due to AEs, An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment., Up to 14 days post-dose
|
